Hopital LARREY
- Address
- 24 Chemin de POUVOURVILLE, 31000 Toulouse, France
Hopital LARREY - Oncology and Immunology Research Center
Hopital LARREY is a specialized medical research center conducting advanced clinical trials in oncology and rare immunological disorders. The center demonstrates particular expertise in innovative cancer therapies, combining immunotherapy with radiation treatment approaches, as well as in the investigation of novel therapeutic agents for complex mast cell-related conditions.
- Advanced non-small cell lung cancer (NSCLC) treatment combining PD-1 inhibitors with concurrent radiotherapy
- Systemic mastocytosis management, focusing on smouldering and indolent severe forms with significant patient impact
- Mast cell activation syndrome (MCAS) therapeutic interventions for treatment-resistant cases
The center's research portfolio reflects a commitment to addressing challenging clinical scenarios in both advanced malignancies and rare immunological disorders. Their work includes phase III trials evaluating masitinib therapy for patients with mastocytosis and mast cell activation syndrome who remain unresponsive to conventional symptomatic treatments, as well as comparative effectiveness studies of combined modality approaches in stage IIIB-IV lung cancer patients eligible for first-line pembrolizumab therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Unicancer1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ab Science2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital LARREY
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Oral Masitinib in Severe Mast Cell Activation Syndrome: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Phase II Study | Ab Science | Phase II | Not Recruiting | Sep 2024 | Jul 2026 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Masitinib | 2 | Unknown | 2024-09-19 | 2025-11-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.